Wednesday, January 23, 2019 Trial Closure: OV18 (ICON6) The lead group (MRC) has informed CCTG that the OV18 (ICON6): A Randomised, Placebo-controlled, Trial of Concurrent Cediranib [AZD2171] (with platinum-based chemotherapy) and Concurrent and Maintenance Cediranib in Women with Platinum-sensitive Relapsed Ovarian Cancer trial, is now been permanently closed/terminated. Primary Publication: Ledermann JA, Embleton AC, Raja F, Perren TJ, Jayson GC, Rustin GJS, Kaye SB, Hirte H, Eisenhauer E, Vaughan M, Friedlander M, González-Martín A, Stark D, Clark E, Farrelly L, Swart AM, Cook A, Kaplan RS, Parmar MKB Cediranib in patients with relapsed platinum-sensitive ovarian cancer (ICON6): a randomised, double-blind, placebo-controlled phase 3 trial :387(10023):1066 -1074,2016 The notification of permanent trial closure is posted on the CCTG website under the "Toolbox" here: https://www.ctg.queensu.ca/trials/permanent_closure/permanent-trial-closure/ Trial Closure: IND.218 The IND.218 trial has been formally permanently closed/terminated. No further ethics approvals or folow up data are required. The IND.218 trial: A Study of Vinblastine and Temsirolimus in Pediatric Patients with Recurrent or Refractory Lymphoma or Solid Tumours Including CNS Tumours will be permanently closed/terminated as of tomorrow, 2019Jan16. Primary publication: Phase I study of vinblastine and temsirolimus in pediatric patients with recurrent or refractory solid tumors: Canadian Cancer Trials Group Study IND.218. Rebecca J. Deyell, Bing Wu, S. Rod Rassekh, Dongsheng Tu, Yvan Samson, Adam Fleming, Eric Bouffet, Xiaoqun Sun, Jean Powers, Lesley Seymour, Sylvain Baruchel, Daniel A. Morgenstern The notification of permanent trial closure is posted on the CCTG website under the "Toolbox" here: https://www.ctg.queensu.ca/trials/permanent_closure/permanent-trial-closure/ Trial Closure: MA28 (NCCTG N9831) The MA28 (NCCTG N9831) trial has been formally permanently closed/terminated. No further ethics approvals or folow up data are required. The notification of permanent trial closure is posted on the CCTG website under the "Toolbox" here: https://www.ctg.queensu.ca/trials/permanent_closure/permanent-trial-closure/ MA28 (NCCTG N9831): Phase III Trial of Doxorubicin and Cyclophosphamide (AC) Followed by Weekly Paclitaxel With or Without Trastuzumab as Adjuvant Treatment For Women With HER-2 Over-Expressing or Amplified Node Positive or High-Risk Node Negative Breast Cancer Primary publication: J Clin Oncol. 2011 Dec 1;29(34):4491-7. doi: 10.1200/JCO.2011.36.7045. Epub 2011 Oct 31. Sequential versus concurrent trastuzumab in adjuvant chemotherapy for breast cancer. Perez EA1, Suman VJ, Davidson NE, Gralow JR, Kaufman PA, Visscher DW, Chen B, Ingle JN, Dakhil SR, Zujewski J, Moreno-Aspitia A, Pisansky TM, Jenkins RB. Trial Closure: CE2 (RTOG 94-02) The CE2 trial has been formally permanently closed/terminated. No further ethics approvals or folow up data are required. CE2 (RTOG 94-02): Phase III Intergroup Randomized Comparison of Radiation Alone versus Pre-radiation Chemotherapy For Pure and Mixed Anaplastic Oligodendrogliomas, has been permanently closed/terminated. This trial was activated in 1996Oct23 and closed to accrual 2002Mar29. The notification of permanent trial closure is posted on the CCTG website under the "Toolbox" here: https://www.ctg.queensu.ca/trials/permanent_closure/permanent-trial-closure/
